Biopharma Daily Stock Updates - 01/08/21

Updated: Jan 13

$XBI $149.54 (+0.22%) 📈


COVID:

$BNTX (+7.15%) - An In Vitro Study Shows Pfizer-BioNTech COVID-19 Vaccine Elicits Antibodies that Neutralize SARS-CoV-2 with a Mutation Associated with Rapid Transmission

https://biontechse.gcs-web.com/news-releases/news-release-details/vitro-study-shows-pfizer-biontech-covid-19-vaccine-elicits


$MRNA (-2.03%) - United Kingdom Medicines and Healthcare products Regulatory Agency Authorizes Use of COVID-19 Vaccine Moderna

https://investors.modernatx.com/news-releases/news-release-details/united-kingdom-medicines-and-healthcare-products-regulatory


PIPELINE:

$NLTX (-10.96%) - Neoleukin Therapeutics Receives Clinical Hold Letter from U.S. FDA Related to CMC Assay Development for NL-201

http://investor.neoleukin.com/news-releases/news-release-details/neoleukin-therapeutics-receives-clinical-hold-letter-us-fda


$CMRX (+69.08) - Chimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage Oncology Program

https://ir.chimerix.com/news-releases/news-release-details/chimerix-acquires-oncoceutics-expand-pipeline-late-stage


$TCRR (+7.77%) - TCR² Therapeutics Announces 2021 Strategic Priorities and Milestones

https://investors.tcr2.com/news-releases/news-release-details/tcr2-therapeutics-announces-2021-strategic-priorities-and


FINANCIAL:

ALDX (+21.72%) - Citigroup Maintains Buy on Aldeyra Therapeutics, Lowers Price Target to $22

https://www.benzinga.com/news/20/08/17027493/citigroup-maintains-buy-on-aldeyra-therapeutics-lowers-price-target-to-22


$KMPH - KemPharm Announces Pricing of $50 Million Public Offering of Common Stock and Warrants and Uplisting to The Nasdaq Capital Market

https://investors.kempharm.com/news-releases/news-release-details/kempharm-announces-pricing-50-million-public-offering-common


$RGNX (-5.11%) - REGENXBIO Announces Pricing Of Public Offering Of Common Stock

http://ir.regenxbio.com/news-releases/news-release-details/regenxbio-announces-pricing-public-offering-common-stock-1



0 comments

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon